| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
ABT-737 (12.5 μM) and glycoumarin (25 μM; 24 h) work together to synergistically promote cell death in different hepatoma HepG2 cell types [2]. Through mechanisms like activating the Nrf2 antioxidant system, stimulating AMPK-mediated energy homeostasis, inducing the autophagy degradation process, and inhibiting oncogenic kinases, glycycoumarin prevents alcoholic liver disease, non-alcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer. Strong protein kinase activity generated by killer cell-activated T-lymphokines [3].
|
|---|---|
| ln Vivo |
Licoumarin (30 μM-0.3 nM; 5 minutes) inhibits PDE, particularly isoenzyme 3, which causes intracellular cAMP to accumulate and prevents smooth muscle contraction brought on by different stimulants [1]. In a mouse HepG2 xenograft model, glycycoumarin (10 mg/kg; i.p.; once daily for 4 days) improves tumor growth suppression and shows synergistic benefits with ABT-737 [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: HepG2, SMMC-7721 and Huh-7 Tested Concentrations: 10, 20, 25, 30 and 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced death of multiple liver cancer cell lines in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice (6 weeks old, weight 25-30 grams) [1]
Doses: 30 μM-0.3 nM, 5 minutes Route of Administration: Experimental Results: Inhibition of CCh, KCI, BaCI(2) and A23187 (calcium Ionophore III). Enhances the relaxing effect of forskolin on CCh-induced contractions and also enhances the relaxing effect of rolipram. Associated with dose-dependent accumulation of cAMP. Animal/Disease Models: Male BALB/c athymic nude mice (6-7 weeks old) HepG2 cancer cell xenograft model [2] Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection; intraperitoneal (ip) injection. one time/day for 4 days; ABT-737 group received intraperitoneal (ip) injection of 100 mg/kg. Experimental Results: Inhibited tumor growth and diminished final tumor weight by 17%. |
| References | |
| Additional Infomation |
Glycycoumarin is a member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 5, a prenyl group at position 6 and a 2,4-dihydroxyphenyl group at position 3. Isolated from Glycyrrhiza uralensis, it exhibits antispasmodic activity. It has a role as an antispasmodic drug and a plant metabolite. It is a member of coumarins, an aromatic ether and a member of resorcinols.
Glycycoumarin has been reported in Glycyrrhiza uralensis, Glycyrrhiza aspera, and other organisms with data available. See also: Glycyrrhiza uralensis Root (part of). |
| Molecular Formula |
C21H20O6
|
|---|---|
| Molecular Weight |
368.3799
|
| Exact Mass |
368.125
|
| CAS # |
94805-82-0
|
| PubChem CID |
5317756
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
646.9±55.0 °C at 760 mmHg
|
| Melting Point |
243.5-244.5℃
|
| Flash Point |
232.0±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
5.99
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NZYSZZDSYIBYLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20O6/c1-11(2)4-6-14-18(24)10-19-16(20(14)26-3)9-15(21(25)27-19)13-7-5-12(22)8-17(13)23/h4-5,7-10,22-24H,6H2,1-3H3
|
| Chemical Name |
3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methylbut-2-enyl)chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~678.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.65 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL | |
| 5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL | |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
